Barinthus Biotherapeutics (BRNS) Short term Debt (2021)
Barinthus Biotherapeutics' (BRNS) quarterly Short term Debt came in at $159000.0 in Q4 2021.
Barinthus Biotherapeutics (BRNS) Short term Debt (2021) Analysis & Trends
Barinthus Biotherapeutics (BRNS) has 1 years of Short term Debt data on file, last reported at $159000.0 in Q4 2021.
- Quarterly Short term Debt changed N/A year-over-year to $159000.0 in Q4 2021, while the trailing twelve-month figure through Dec 2021 was $159000.0 (changed N/A YoY) and the FY2021 annual result came in at $159000.0, changed N/A from the prior year.
- Short term Debt was little changed at $159000.0 in Q4 2021.
- In the past five years, Short term Debt ranged from a high of $159000.0 in Q4 2021 to a low of $159000.0 in Q4 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.97 Bn | 132.12 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.64 Bn | 78.64 Bn | 3.93 Bn |
| 3 | Argenx Se | 65.55 Bn | 60.37 Bn | 1.37 Bn |
| 4 | Moderna | 61.26 Bn | 56.12 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 42.30 Bn | 37.20 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.66 Bn | 28.35 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.68 Bn | 10.29 Bn | 668.28 Mn |
| 8 | Insmed | 27.54 Bn | 26.38 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.26 Bn | 26.42 Bn | - |
| 10 | Barinthus Biotherapeutics | 25.29 Mn | 25.29 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | 159,000.00 |